Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
A large PCAB-accredited Florida 503A compounder with explicit compounded semaglutide/tirzepatide, peptides, and HRT — a leading telehealth-partner pharmacy.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
Hallandale is one of the larger consumer-facing 503A compounders — the kind of patient-specific pharmacy that fills prescriptions routed through telehealth practices. It’s a 503A (state-regulated, patient-specific), not a 503B outsourcing facility.
Hallandale operates as a 503A pharmacy (legal entity “Pharmcore, LLC” dba Hallandale Pharmacy, Fort Lauderdale, FL); it is not on the FDA 503B outsourcing-facility list [3]. We independently confirmed its PCAB accreditation in ACHC’s own directory — listed under Pharmcore / Hallandale Pharmacy, Fort Lauderdale, FL, PCAB Compounding Pharmacy [2]. The company says it has operated since 2003 from a ~60,000-sq-ft facility, working with thousands of practitioners and shipping nationwide [1].
Explicitly on-audience: weight management with compounded semaglutide (2.5 and 5 mg/mL) and tirzepatide (10 and 15 mg/mL), a dedicated peptide-therapy line, hormone replacement, sexual wellness, dermatology, fertility, and IV therapy [1].
As a 503A pharmacy, Hallandale’s primary oversight is Florida’s board of pharmacy rather than FDA CGMP inspection, so there is less federal paper trail. We found no FDA warning letter for Hallandale/Pharmcore in public sources, and it does not appear on the FDA 503B list [3]. As always with 503A, absence from federal databases is not an exhaustive clean record.
Among the strongest “pure 503A telehealth-partner” options in the set: PCAB-accredited (independently confirmed), explicit compounded GLP-1 and peptide lines, long operating history, national reach. The 503A model means state-board oversight rather than FDA CGMP — the standard trade-off versus a 503B like Empower.